Fulcrum Therapeutics is committed to developing disease modifying treatments that result in meaningful outcomes for patients, caregivers, families, and medical teams. We seek partnerships with patients and caregivers to inform our work.
About Patient Advocacy at Fulcrum
We acknowledge the significant unmet medical need faced by people living with sickle cell disease (SCD) and their families.
We invite you to learn more about how we actively
partner with patients, advocacy organizations, and
healthcare providers to inform our work in SCD.
Build Trust
Cultivate relationships with the patient, caregiver, and advocacy community founded on trust and respect.
Engage Communities
Develop an active presence in patient communities and professional societies.
Support Access
Partner with the patient community to support disease education, access, and advocacy activities.
Amplify Voices
Incorporate the patient voice in Fulcrum’s work and represent Fulcrum in the patient community.
Partnering with the Sickle Cell Community
We aim to build trusting relationships with patients and advocacy groups to ensure the patient voice guides our work and supports disease education.
We work towards this by:
Engaging in dialogue
Regular collaboration with the SCD community to understand needs and priorities.
Maintaining presence
Active participation at patient conferences, community events, and professional societies.
Supporting policy advocacy
Partnering with patient organizations to improve access and outcomes.
Integrating patient perspectives
Throughout our drug development process—from clinical trial design to access planning.
“Our mission and our focus is to find better treatment options for people living with sickle cell disease. And that is at the heart of everything that we do.”
— Alex Sapir, President and CEO
Our Team
Meet the dedicated professionals leading Fulcrum’s patient advocacy efforts.
Sara Johnson Davis
Vice President, Head of Patient Advocacy & Policy
Sara leads Fulcrum’s patient advocacy strategy, ensuring patient voices are central to our work in sickle cell disease and beyond.
Hear from members of the sickle cell community about their experiences, challenges, and hopes for the future.
Advocacy is connection
Patient Voices
5 Videos
0:16
0:16
0:16
0:16
0:16
SCD Resources
Access information about sickle cell disease, clinical research, and community support.
WEBINAR
Exploring New Research in Sickle Cell Disease: Fulcrum Updates from the Pioneer Study.
Monday, March 30, 2026
On March 30, Fulcrum’s leadership hosted a webinar on updates from the Pioneer trial, including 12-week data from the 20-milligram cohort, with guest speaker and leading SCD researcher Dr. Martin Steinberg. This event followed a September 2025 webinar focused on data from the 12-milligram cohort.
WEBINAR
Clinical Data Presentation (September 2025)
Monday, September 29, 2025
Learn about the promising results from our PIONEER study, featuring insights from Fulcrum leadership and leading sickle cell specialists Dr. Shenya Allen (Inova Fairfax) and Dr. Wally Smith (Virginia Commonwealth University).
POSTER
Pociredir, a Novel Oral Once-Daily Fetal Hemoglobin Inducer
Results from the phase 1B PIONEER study in adult participants with severe sickle cell disease and hydroxyurea intolerance or unresponsiveness.
Patients or caregivers who are interested in learning more about Fulcrum Therapeutics and our programs can contact us at the email below. For medical advice, please contact your physician.
We will acknowledge receipt of requests as soon as possible, usually within five (5) business days.
PIONEER Study: 20-Milligram Cohort Results
On March 30, Fulcrum’s leadership hosted a webinar on updates from the Pioneer trial, including 12-week data from the 20-milligram cohort, with guest speaker and leading SCD researcher Dr. Martin Steinberg. This event followed a September 2025 webinar focused on data from the 12-milligram cohort.
The Pioneer study is currently in Phase 1b, exploring safety, efficacy, and dosage. Pociredir is in early stages of development.
What You’ll Learn:
Why this matters to you: Learn how fetal hemoglobin plays a role in sickle cell disease
New data update: Building on the 12-milligram cohort findings, Fulcrum will share 12-week data from the 20-milligram patient cohort
What comes next: Fulcrum’s plans for larger trials to further evaluate the safety and efficacy of pociredir
A subject matter expert’s voice: Hear Dr. Martin Steinberg, a pioneer in SCD research, discuss the results
Clinical Data Presentation (September 2025)
Learn about the promising results from our PIONEER study, featuring insights from Fulcrum leadership and leading sickle cell specialists Dr. Shenya Allen (Inova Fairfax) and Dr. Wally Smith (Virginia Commonwealth University).
What You’ll Learn:
Fulcrum’s 5 ideal criteria for developing an SCD therapy
The role of fetal hemoglobin in improving patient outcomes
PIONEER study results showing significant improvements in HbF levels
What these results mean for the SCD patient community
What these results mean for the SCD patient community